ACLX Live signals | Maximize Profits with Getagraph.com

SELL 157884 min ago

@ $63.29

Issued: 14 Feb 2024 @ 09:30

Return: -17.83%

Previous signal: Feb 12 - 13:39

Previous signal: Buy

Return: -0.81 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases...

Stats
Today's Volume	474 700
Average Volume	469 077
Market Cap	2.78B
EPS	$0 ( 2024-05-13 )
Next earnings date	( $-0.520 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-50.49
ATR14	$0.0700 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-23	Gilson Michelle	Buy	22 428	Common Stock
2024-05-23	Gilson Michelle	Sell	22 428	Restricted Stock Units
2024-05-24	Gilson Michelle	Sell	12 121	Common Stock
2024-05-01	Heery Christopher	Sell	10 000	Stock Option (right to buy)
2024-05-01	Heery Christopher	Buy	18 168	Common Stock

INSIDER POWER
-46.12
Last 100 transactions
Buy: 1 157 076 \| Sell: 3 777 072

Volume Correlation

Long: 0.67 (moderate)

Short: 0.57 (weak)

Signal:(65.077) Neutral

Arcellx, Inc. Correlation

10 Most Positive Correlations
OZEM	1
JDZG	0.922
SHMDW	0.906
ROST	0.898
BAYA	0.893
NEWZ	0.892
OCMAX	0.892
SKIRX	0.889
CBHAX	0.888
SVRE	0.886

10 Most Negative Correlations
ARBB	-0.925
ENGN	-0.91
FATBW	-0.904
AAME	-0.889
KWE	-0.888
CHUY	-0.887
JTAI	-0.883
BNZI	-0.881
LUXH	-0.879
SHIM	-0.879

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arcellx, Inc. Correlation - Currency/Commodity

0.02
( neutral )

0.16
( neutral )

0.00
( neutral )

-0.48
( neutral )

-0.12
( neutral )

Arcellx, Inc. Financials

Annual	2023
Revenue:	$110.32M
Gross Profit:	$108.28M (98.15 %)
EPS:	$-1.470

FY	2023
Revenue:	$110.32M
Gross Profit:	$108.28M (98.15 %)
EPS:	$-1.470

FY	2022
Revenue:	$0
Gross Profit:	$-2.22M (0.00 %)
EPS:	$-4.22

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-6.02

Financial Reports:

No articles found.

Arcellx, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Arcellx, Inc.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.